tbuckley/cabot-search huggingface dataset:
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
Authors: Wanbo Tai, Lei He, Xiujuan Zhang, Jing Pu, Denis Voronin, Shibo Jiang, Yusen Zhou, Lanying Du
Journal: Cellular and Molecular Immunology (2020)

Abstract The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection.
Phase II screening study to assess the combination of a LHRH analogue, dexamethasone and a somatostatin analogue versus a LHRH analogue with dexamethasone in hormone refractory prostate cancer patients
Authors: F. Silva, F. M. Calais Da Silva, F. Gonçalves, T. Oliver
Journal: Journal of Clinical Oncology (2006)

4565 Background: Hormonal changes and the possible resulting imbalance between androgen and estrogen levels in elderly men may play an important role in prostatic pathogenesis. Androgen suppression can induce regression of prostatic carcinoma. Ample laboratory and clinical research have contributed to evidence that a direct link exists between prostatic cell growth, prostatic carcinoma cell growth and hormones, mainly testicular androgens. As far as prostatic cancer is concerned, we know that SMS blocks GH, PRL, tissular growth factors (TGF) and that it has a direct antiproliferative growth cellular growth effect. The simultaneous administration of depot forms of SMS and LHRH analogues induced the greatest decrease in tumor growth. Methods: A randomized Phase II trial was carried out in M0 (PSA ≥ 20 ng/ml) and M1 patients with hormone refractory prostate cancer to simultaneously screen decapeptyl and dexamethasone, both with and without somatulin (120 mg every 4 weeks), with respect to PSA response rate, time to PSA progression, duration of survival and toxicity. Results: 72 patients with a median time PSA of 77 ng/ml were randomized by 3 institutions, 35 to decapeptyl, dexamethasone and somatulin (DDS) and 37 to decapeptyl and dexamethasone (DD). 21 of 33 (64%) patients on DDS and 21 of 32 on DD (66%) had a PSA response (a decrease of at least 50 % as compared to baseline). The median duration of PSA response was 6.6 months on DDS and 3.4 months on DD. Overall, the median time to PSA progression was 5.8 months on DDS and 1.8 months on DD. The median duration of survival has not yet been reached. Both treatment regimens were well tolerated. The most frequent toxicities on DDS and DD were hot flushes (27%, 10%), gastrointestinal (18%, 20%), and skin complaints (12%, 10%). Conclusions: Both treatment regimens are active and safe in the treatment of hormone refractory prostate cancer. Although the PSA response rate is about 65%, the median duration of response and median time to progression were longer in the somatulin arm; so, the data suggest a possible advantage of DDS with respect to both the duration of the PSA response and the time to PSA progression. Further follow-up is required to assess survival. No significant financial relationships to disclose.
QIM20-125: OBESE: Oncologist Based Emphasis on Survivor Education-Physician Driven Weight Loss Counseling and Outcomes in TNBC
Authors: Marwah W. Farooqui, Caitlin Carter, Nicholas Gustafson, Saherish Abbasi, Sravani Sagireddy, Kathryn Hockensmith, Amy Stein, Masood Ghouse, Krishan Srinivasan
Journal: Journal of the National Comprehensive Cancer Network (2020)
MORBIDITY AND MORTALITY IN ADULT FONTAN PATIENTS AFTER HEART OR COMBINED HEART LIVER TRANSPLANT: A REPORT FROM THE FOSTER STUDY
Authors: Matthew J. Lewis, Leigh Reardon, Jamil A. Aboulhosn, Christiane Haeffele, Sharon Chen, Yuli Kim, Wendy Book, Fred Rodriguez, Anne Marie Valente, Matthew Carazo, Eric Krieger, Jilian Angiulo, Alexander Egbe, Ari M. Cedars, Jong Ko, Roni Jacobson, Michael Earing, Peter Ermis, Chris Broda, Jonathan W. Cramer, Natalia Nugaeva, Heather Joan Ross, Richard A. Krasuski, Marlon Rosenbaum
Journal: Journal of the American College of Cardiology (2020)
Forecasting the efficiency of chemoradiotherapy in patients having disseminated melanoma of skin.
Authors: Yekaterina Komarova, Yelena Frantsiyants, Farhad Dzhabarov, Ludmila Rozenko, Victoria Pozdnyakova
Journal: Journal of Clinical Oncology (2013)

e20005 Background: Result of scientific research testify that particularities of endocrinal status might play a role in etiology and pathogenesis of illness. In connection to this, studying of particularities of hormonal homeostasis in patients having skin melanoma becomes relevant, as on the background of the former, the tumor develops this or that reaction to remedial measures. Methods: Content of triiodothyronine (T3) in peripheral blood was studied in 40 patients of both sexes having disseminated melanoma of skin (pT2-3N1-2M0) before and after chemoradiation. Chemotherapy consisted of dacarbazine in course dose of 1000 mg/m2, radiotherapy – total boost dose was 55+5,4 Gy. Results: Assessment of direct clinical result of the complex of antitumor measures has demonstrated that in the group of patients under control the treatment proved inefficient in 15 people and was not accompanied by decrease of tumor formation sizes, while in 25 people the curative effect was manifested in 25-50% (15 cases) regress of tumor lesions and in over 50% (10 cases) regress. Conclusions: The results of chemoradiation were analyzed depending on the initial content of general T3 in the blood of the patients. It has been discovered that absence of effect from treatment was featured in patients having low content of the hormone – from 0,52 to 1,10 nmole/l, normal oscillations of its level in healthy people being 1,2 to 2,8 nmole/l. Contrary to that, in patients having regress of tumor, the initial concentration of the hormone ranged from 1,35 to 1,70 nmole/l, i.e. within the physiological norm.
EVALUATION OF LDL-C REDUCTIONS BY SIRNA TREATMENT WITH INCLISIRAN IN PATIENTS WITH DIABETES MELLITUS, METABOLIC SYNDROME OR NEITHER
Authors: R. Scott Wright, David Kallend, Kausik Kumar Ray, Lawrence Leiter, Wolfgang Koenig, Frederick Raal, Peter Wijngaard, John J.P. Kastelein
Journal: Journal of the American College of Cardiology (2020)
Abstract 14802: Chronic Tadalafil Therapy Improves Fasting Glucose Levels And Downregulates Microrna-103 And -107 In Obese Diabetic Mice
Authors: Amit Varma, Arun Samidurai, Fadi N Salloum, Rakesh C Kukreja
Journal: Circulation (2012)

Background: MicroRNAs (MiRs) are small non-coding RNAs that regulate gene expression in a sequence dependent manner. Two related miRs (miR-103/107) are powerful negative regulators of insulin sensi...
Distinct maternal microbiota clusters are associated with diet during pregnancy: impact on neonatal microbiota and infant growth during the first 18 months of life
Authors: Izaskun García-Mantrana, Marta Selma-Royo, Sonia González, Anna Parra-Llorca, Cecilia Martínez-Costa, María Carmen Collado
Journal: Gut Microbes (2020)

Nutrition during pregnancy plays an important role in maternal-neonatal health. However, the impact of specific dietary components during pregnancy on maternal gut microbiota and the potential effects on neonatal microbiota and infant health outcomes in the short term are still limited. A total of 86 mother-neonate pairs were enrolled in this study. Gut microbiota profiling on maternal-neonatal stool samples at birth was carried out by 16S rRNA gene sequencing using Illumina. Maternal dietary information and maternal-neonatal clinical and anthropometric data were recorded during the first 18 months. Longitudinal Body Mass Index (BMI) and Weight-For-Length (WFL) z-score trajectories using the World Health Organization (WHO) curves were obtained. The maternal microbiota was grouped into two distinct microbial clusters characterized by Prevotella (Cluster I) and by the Ruminococcus genus (Cluster II). Higher intakes of total dietary fiber, omega-3 fatty acids, and polyphenols were observed in Cluster II compared to Cluster I. Higher intakes of plant-derived components were associated with a higher presence of the Christensellaceae family, Dehalobacterium and Eubacterium, and lower amounts of the Dialister and Campylobacter species. Maternal microbial clusters were also linked to neonatal microbiota and infant growth in a birth-dependent manner. C-section neonates from Cluster I showed the highest BMI z-score at age 18 months, along with a higher risk of overweight. Longitudinal BMI and WL z-score trajectories from birth to 18 months were shaped by maternal microbial cluster, diet, and birth mode. Diet was an important perinatal factor in early life that may impact maternal microbiota; in particular, fiber, lipids and proteins, and exert a significant effect on the neonatal microbiome and contribute to infant development during the first months of life.NCDs: Non-Communicable Diseases, C-section: Cesarean Section, BMI: Body Mass Index; WL: Weight for length; EPA: Eicosapentanoic Acid; DHA: Docosahexaenoic Acid; DPA: Docosapentaenoic Acid; SCFA: Short Chain Fatty Acids; MD: Mediterranean Diet; FFQ: Food Frequency Questionnaire; CHI: Calinski Harabasz Index.
Glucocorticoid withdrawal in lupus – to do or not to do?
Authors: Nupoor Acharya
Journal: Annals of the Rheumatic Diseases (2020)

I read with great interest, the recently published article in your journal titled “Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial” by Mathian et al .1 The discussion on the feasibility of completely stopping glucocorticoids in systemic lupus erythematosus (SLE) has been ongoing and it poses a practical challenge to every physician treating SLE. Besides the adverse effects, studies also suggest that long term glucocorticoid therapy for remission maintenance in SLE leads to increased accrual of organ damage.2 The effect of withdrawal of glucocorticoids on SLE …
The lymphoid chemokine CCL19 (ELC) promotes T cell proliferation in vitro and mediates T cell migration when expressed in a recombinant vaccinia virus: A strategy for local tumor vaccine delivery
Authors: Kenneth Flanagan, Heidi Hörig, Howard Kaufman
Journal: Cancer Research (2004)

657  Chemokines are small secreted proteins involved in regulating immune responses through their ability to attract and activate immune cells providing a powerful tool for manipulating the tumor microenvironment. CCL21 (SLC/6Ckine) and CCL19 (ELC/ MIP-3β) coordinate the attraction of mature dendritic cells (DC) and naive T cells in secondary lymphoid tissue. We have previously shown that intratumoral injection of a recombinant vaccinia virus expressing CCL21 attracts T cells to the tumor site and initiates CD4 T cell mediated anti-tumor responses. We now report the expression of CCL19 by a recombinant vaccinia virus (rV-ELC) for the local delivery of high levels of CCL19 to established tumors. The rV-ELC vaccine is stable and expresses functional CCL19 as evidenced by migration of murine T lymphocytes in in vitro chemotaxis assays. Furthermore, CCL19 was able to potently co-stimulate T cell proliferation in conjunction with sub-optimal T cell receptor stimulation in vitro. We plan to explore this novel function of CCL19 by determining the expression of known cell surface T cell activation markers and exploring which signal transduction pathways are required for CCL19 mediated co-stimulation. The ability of CCL19 to attract and expand specific T cell populations, coupled with the high levels of expression by poxviral vectors, provides a mechanism for promoting T cell priming within the local tumor microenvironment. This approach has implications for the therapy of cancer and infectious disease.
Peroral endoscopic septotomy for short-septum Zenker’s diverticulum
Authors: Alessandro Repici, Marco Spadaccini, Paul James Belletrutti, Piera Alessia Galtieri, Alessandro Fugazza, Andrea Anderloni, Silvia Carrara, Milena Di Leo, Gaia Pellegatta, Annalisa Cappello, Carlo Castoro, Yervant Ichkhanian, Mouen A. Khashab, Roberta Maselli
Journal: Endoscopy (2020)

Abstract Background Treatments of Zenker’s diverticulum aim to dissect the cricopharyngeal muscle, removing the underlying source of dysfunction. This is difficult in patients with a short-septum (≤ 20 mm) diverticulum because the limited anatomical space restricts the operating area for either rigid or flexible endoscopic approaches. The aim of this study was to investigate the efficacy and safety of a novel third-space approach, peroral endoscopic septotomy (POES), for treating symptomatic patients with short-septum Zenker’s diverticulum. Methods All patients with short-septum Zenker’s diverticulum who were referred for endoscopic repair from September 2017, were considered for the study. Outcomes included procedure-related adverse events and symptom improvement. The Dakkak – Bennett score was used to quantify dysphagia. Results 20 patients (men 12, women 8; mean age 67.9 years [SD 14.3]) underwent POES. All procedures were performed with patients under deep sedation. Mean size of Zenker’s diverticulum was 17.5 mm (SD 3.0) and mean dysphagia score was 2.7 (SD 0.5). Average procedure time was 13.8 minutes (SD 5.1). No intra- or post- procedural adverse events occurred. Septal myotomy was successfully completed in all patients. Dysphagia significantly improved in 19 out of 20 patients. Dakkak – Bennett score improved to 0.3 (SD 0.5), P &lt; 0.0001). No recurrences were reported in a mean follow-up time of 12.0 months (SD 3.7, range 6 – 20). Conclusions POES may be considered as a potential alternative for the treatment of short-septum Zenker’s diverticulum. Further data are required to validate this technique and compare it with already available rigid and flexible approaches.
RIGHT VENTRICULAR FUNCTION COUPLING TO THE PULMONARY CIRCULATION PREDICTS EXERCISE TOLERANCE IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHT FROM THE EVALUATION OF RESYNCHRONIZATION THERAPY FOR HEART FAILURE (EARTH) TRIAL
Authors: Valéry Legris, Bernard Thibault, Jocelyn Dupuis, Michel White, Annik Fortier, Christine Henri, Eileen O'Meara, Anique Ducharme
Journal: Journal of the American College of Cardiology (2020)
Assuring dietary supplement quality for cancer patients: An integrated formulary systems approach.
Authors: Maurie Markman, Michael Levin, Paul Reilly, Joseph W. Coyne, Carolyn Lammersfeld, Timothy C. Birdsall
Journal: Journal of Clinical Oncology (2013)

e20663 Background: Studies reveal up to 80% of cancer patients use some form of dietary supplements (DS). Despite the need for additional research, evidence exists that some DS may be of clinical value. In order to provide safe DS recommendations to patients, we created a Dietary Supplement Formulary Committee (DSFC). Methods: Twelve manufacturers (marketing 19 DS brands) with a reasonable reputation among providers for quality were selected. A survey tool was created to measure critical quality, GMP and FDA compliance practices; information was obtained via non-disclosure agreements; manufacturing documents were audited and compared to survey responses; FDA audit reports were obtained under Freedom of Information requests; site audits were conducted; and third party analytical testing was performed. Results: All 12 companies claimed to be operating in full compliance with FDA regulations. However, 3 had received Warning Letters from FDA for GMP violations; 2 performed a product recall within the last 5 years; 4 reported products that failed Consumerlab.com for potency or purity; 1 did not have product specifications; 1 was found by FDA to have inadequate testing; 1 was found to have a lack of sufficient controls throughout the supply chain to guard against microbiological contamination; and 2 had confirmed melamine contamination or lack of melamine testing on protein powders. Additional concerns included the use of subcontractors for certain operations, lack of stability data to support expiration dates, material discrepancies between claims and actual practice, and failure to change UPC (Universal Product Code) numbers when active ingredient formulas change. Conclusions: We observed considerable variation in the quality of DS, and in the level of compliance, which raises concerns for patient safety. One company met all quality standards. The combined use of the measures described above allowed for informed product selection. The variable quality practices identified here emphasize the need for careful formulary oversight. The USP (United States Pharmacopeial Convention), ConsumerLab.com, and the NSF International’s certification programs are current resources available to help identify quality DS.
Genes involved in EGFR-degradation to predict for efficacy in metastatic colorectal cancer patients treated with cetuximab.
Authors: Sebastian Stintzing, Wu Zhang, Takeru Wakatsuki, Yan Ning, Nico Benjamin Volz, Joseph Ethan Li, Melissa Janae Labonte, Peter M. D. Wilson, Adel Kardosh, Fotios Loupakis, Lisa Salvatore, Marta Schirripa, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2013)

3557 Background: As many transmembrane receptors, the epithelial growth factor receptor (EGFR) has a highly regulated turnover leading to inactivation and recycling or degradation after activation. This process can be divided into four different phases: receptor endocytosis, ubiquitation/neddylation, recycling and degradation. We tested whether functional significant single nucleotide polymorphisms in genes involved in the degradation pathway will predict clinical outcome (response, PFS and OS) in 108 patients with metastatic colorectal cancer enrolled in clinical trials and treated with cetuximab. Methods: Genomic DNA was isolated from blood from 108 patients treated with cetuximab enrolled in one of two clinical trials. All patients were KRAS and BRAF wildtyp. 20 SNPs were selected based on the involvement in receptor endocytosis (CBL, CIN85, endophilin) ubiquitation/neddylation, recycling and degradation (CBL, EPS15, Ubc12, UbcH7). Minor allele frequency had to by higher than 10%. PCR and product sequencing were done using standard procedures. Uni- and multivariate analyses, adjusting for age, gender, rash and racial background, were carried out. Results: In univariate analysis, rs895374 (HR: 1.69; p= 0.03), which is located in the exome of UbcH7, was able to separate patient cohorts significantly in perspective of progression free survival (CC = 5.7mo, CA= 3.6mo, AA= 3.4mo). Using multivariate analysis, rs895375 stayed to be a significant predictor of progression free survival with a Hazard ratio of 2.08 (95% CI 1.24 – 3.48) and a p value of 0.005. UbcH7 plays a pivotal role in the process of neddylation (adding NEDD8 to the EGFR), which switch the balance between recycling and degradation of the EGFR towards degradation. Conclusions: The process of EGFR recycling is important mechanism of resistance of cetuximab in colorectal cancer. This is the first report suggesting that germline polymorphisms in the degradation process may predict efficacy of cetuximab in patients with metastatic colorectal cancer. Anti-EGFR antibody like Sym004 might overcome this resistance mechanism by preventing EGFR recycling.
EPR20-073: The Effects of Chemotherapy on the Efficacy of Pneumococcal Vaccination Using Pneumococcal Vaccine Antibody Titers as Correlate
Authors: Matthew Rendo, Robert Sgrignoli, Wilfred Dela Cruz
Journal: Journal of the National Comprehensive Cancer Network (2020)

"EPR20-073: The Effects of Chemotherapy on the Efficacy of Pneumococcal Vaccination Using Pneumococcal Vaccine Antibody Titers as Correlate" published on 20 Mar 2020 by National Comprehensive Cancer Network.
The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis
Authors: Leonardo Martinez, Olivia Cords, C Robert Horsburgh, Jason R Andrews, Carlos Acuna-Villaorduna, Shama Desai Ahuja, Neus Altet, Orvalho Augusto, Davit Baliashvili, Sanjay Basu, Mercedes Becerra, Maryline Bonnet, W. Henry Boom, Martien Borgdorff, Fadila Boulahbal, Anna Cristina C. Carvalho, Joan A. Cayla, Tsira Chakhaia, Pei-Chun Chan, Ted Cohen, Julio Croda, Sumona Datta, Helena del Corral, Justin T. Denholm, Reynaldo Dietze, Claudia C. Dobler, Simon Donkor, Uzochukwu Egere, Jerrold J. Ellner, Marcos Espinal, Carlton A. Evans, Chi-Tai Fang, Katherine Fielding, Greg J. Fox, Luis F. García, Alberto L. García-Basteiro, Steffen Geis, Stephen M. Graham, Louis Grandjean, Djohar Hannoun, Mark Hatherill, Anja M. Hauri, Anneke C. Hesseling, Philip C. Hill, Li-Min Huang, Helena Huerga, Rabia Hussain, Leah Jarlsberg, Edward C. Jones-López, Seiya Kato, Midori Kato-Maeda, Beate Kampmann, H. Lester Kirchner, Afrânio Kritski, Christoph Lange, Chih-Hsin Lee, Li-Na Lee, Meng-Rui Lee, Antonio Carlos Lemos, Christian Lienhardt, Du-Lin Ling, Qiao Liu, Nathan C. Lo, Richard Long, Elisa Lopez-Varela, Peng Lu, Matthew Magee, LaShaunda L. Malone, Anna M. Mandalakas, Neil A. Martinson, Rufaida Mazahir, Megan B. Murray, Eduardo Martins Netto, Larissa Otero, Julie Parsonnet, Arthur Reingold, H. Simon Schaaf, James A. Seddon, Surendra Sharma, Jitendra Singh, Sarman Singh, Rosa Sloot, Giovanni Sotgiu, Catherine M. Stein, Najeeha Talat Iqbal, Rina Triasih, Lisa Trieu, Maarten F Schim van der Loeff, Patrick Van der Stuyft, Cari van Schalkwyk, Richa Vashishtha, Lilly M Verhagen, Julian A. Villalba, Jann-Yuan Wang, Christopher C. Whalen, Takashi Yoshiyama, Heather J. Zar, Jean-Pierre Zellweger, Limei Zhu
Journal: The Lancet (2020)
THE LEVEL OF HYPERCOAGULABILITY AND ITS IMPACT ON CLINICAL OUTCOMES ACCORDING TO THE DISEASE ENTITY FOLLOWING PERCUTANEOUS CORONARY INTERVENTION
Authors: Jong-Hwa Ahn, Sang-Yeong Cho, Jeong Yoon Jang, Jae Seok Bae, Min Gyu Kang, Kyehwan Kim, Hyun Woong Park, Jin-Sin Koh, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang, Young-Hoon Jeong
Journal: Journal of the American College of Cardiology (2020)